The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancer.
Animals
Antineoplastic Agents
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Azabicyclo Compounds
/ therapeutic use
Carcinoma, Ovarian Epithelial
/ drug therapy
Cell Line, Tumor
Cisplatin
/ therapeutic use
Drug Resistance, Neoplasm
Female
Humans
Mice
Mice, Inbred C57BL
Oligopeptides
/ therapeutic use
Ovarian Neoplasms
/ drug therapy
Cisplatin
Combination therapy
Ovarian cancer
Sigma-2 receptors
Sigma-2/SMAC drug conjugate
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
12 Mar 2022
12 Mar 2022
Historique:
received:
08
12
2021
accepted:
01
03
2022
entrez:
13
3
2022
pubmed:
14
3
2022
medline:
23
3
2022
Statut:
epublish
Résumé
Ovarian cancer is initially responsive to frontline chemotherapy. Unfortunately, it often recurs and becomes resistant to available therapies and the survival rate for advanced and recurrent ovarian cancer is unacceptably low. We thus hypothesized that it would be possible to achieve more durable treatment responses by combining cisplatin chemotherapy with SW IV-134, a cancer-targeted peptide mimetic and inducer of cell death. SW IV-134 is a recently developed small molecule conjugate linking a sigma-2 ligand with a peptide analog (mimetic) of the intrinsic death pathway activator SMAC (second-mitochondria activator of caspases). The sigma-2 receptor is overexpressed in ovarian cancer and the sigma-2 ligand portion of the conjugate facilitates cancer selectivity. The effector portion of the conjugate is expected to synergize with cisplatin chemotherapy and the cancer selectivity is expected to reduce putative off-target toxicities. Ovarian cancer cell lines were treated with cisplatin alone, SW IV-134 alone and a combination of the two drugs. Treatment efficacy was determined using luminescent cell viability assays. Caspase-3/7, - 8 and - 9 activities were measured as complementary indicators of death pathway activation. Syngeneic mouse models and patient-derived xenograft (PDX) models of human ovarian cancer were studied for response to SW IV-134 and cisplatin monotherapy as well as combination therapy. Efficacy of the therapy was measured by tumor growth rate and survival as the primary readouts. Potential drug related toxicities were assessed at necropsy. The combination treatment was consistently superior in multiple cell lines when compared to the single agents in vitro. The expected mechanism of tumor cell death, such as caspase activation, was confirmed using luminescent and flow cytometry-based assay systems. Combination therapy proved to be superior in both syngeneic and PDX-based murine models of ovarian cancer. Most notably, combination therapy resulted in a complete resolution of established tumors in all study animals in a patient-derived xenograft model of ovarian cancer. The addition of SW IV-134 in combination with cisplatin chemotherapy represents a promising treatment option that warrants further pre-clinical development and evaluation as a therapy for women with advanced ovarian cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Ovarian cancer is initially responsive to frontline chemotherapy. Unfortunately, it often recurs and becomes resistant to available therapies and the survival rate for advanced and recurrent ovarian cancer is unacceptably low. We thus hypothesized that it would be possible to achieve more durable treatment responses by combining cisplatin chemotherapy with SW IV-134, a cancer-targeted peptide mimetic and inducer of cell death. SW IV-134 is a recently developed small molecule conjugate linking a sigma-2 ligand with a peptide analog (mimetic) of the intrinsic death pathway activator SMAC (second-mitochondria activator of caspases). The sigma-2 receptor is overexpressed in ovarian cancer and the sigma-2 ligand portion of the conjugate facilitates cancer selectivity. The effector portion of the conjugate is expected to synergize with cisplatin chemotherapy and the cancer selectivity is expected to reduce putative off-target toxicities.
METHODS
METHODS
Ovarian cancer cell lines were treated with cisplatin alone, SW IV-134 alone and a combination of the two drugs. Treatment efficacy was determined using luminescent cell viability assays. Caspase-3/7, - 8 and - 9 activities were measured as complementary indicators of death pathway activation. Syngeneic mouse models and patient-derived xenograft (PDX) models of human ovarian cancer were studied for response to SW IV-134 and cisplatin monotherapy as well as combination therapy. Efficacy of the therapy was measured by tumor growth rate and survival as the primary readouts. Potential drug related toxicities were assessed at necropsy.
RESULTS
RESULTS
The combination treatment was consistently superior in multiple cell lines when compared to the single agents in vitro. The expected mechanism of tumor cell death, such as caspase activation, was confirmed using luminescent and flow cytometry-based assay systems. Combination therapy proved to be superior in both syngeneic and PDX-based murine models of ovarian cancer. Most notably, combination therapy resulted in a complete resolution of established tumors in all study animals in a patient-derived xenograft model of ovarian cancer.
CONCLUSIONS
CONCLUSIONS
The addition of SW IV-134 in combination with cisplatin chemotherapy represents a promising treatment option that warrants further pre-clinical development and evaluation as a therapy for women with advanced ovarian cancer.
Identifiants
pubmed: 35279106
doi: 10.1186/s12885-022-09367-w
pii: 10.1186/s12885-022-09367-w
pmc: PMC8918278
doi:
Substances chimiques
Antineoplastic Agents
0
Azabicyclo Compounds
0
Oligopeptides
0
SW IV-134
0
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
263Subventions
Organisme : NCI NIH HHS
ID : R01 CA163764
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Mol Oncol. 2014 Jul;8(5):956-67
pubmed: 24731702
Nat Commun. 2015 Aug 03;6:7956
pubmed: 26234182
J Clin Oncol. 2019 Jun 1;37(16):1380-1390
pubmed: 31002578
N Engl J Med. 2010 Sep 2;363(10):943-53
pubmed: 20818904
Oncoimmunology. 2014 Apr 29;3:e28541
pubmed: 25050221
Lancet Oncol. 2021 May;22(5):632-642
pubmed: 33862001
Oncol Res. 2003;13(6-10):399-404
pubmed: 12725530
J Clin Oncol. 2003 Sep 1;21(17):3194-200
pubmed: 12860964
Ann Oncol. 2013 Oct;24 Suppl 6:vi24-32
pubmed: 24078660
J Clin Oncol. 2019 Sep 10;37(26):2317-2328
pubmed: 31216226
Lancet. 2015 Jul 18;386(9990):249-57
pubmed: 26002111
Oncologist. 2002;7 Suppl 5:20-8
pubmed: 12324630
Mol Cancer. 2014 Mar 07;13:50
pubmed: 24602489
Apoptosis. 2017 Jul;22(7):898-919
pubmed: 28424988
Cancer Biol Ther. 2012 Jul;13(9):804-11
pubmed: 22669575
J Clin Oncol. 2010 Jul 10;28(20):3323-9
pubmed: 20498395
Eur J Cancer. 2016 May;59:22-33
pubmed: 26998845
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Gynecol Oncol. 2019 Feb;152(2):416-425
pubmed: 30409489
Cancers (Basel). 2020 Jun 17;12(6):
pubmed: 32560564
Cell. 2000 Jul 7;102(1):33-42
pubmed: 10929711
Eur J Obstet Gynecol Reprod Biol. 2009 Oct;146(2):222-6
pubmed: 19758744
Br J Cancer. 2013 Oct 29;109(9):2368-77
pubmed: 24104966
NPJ Precis Oncol. 2017;1:
pubmed: 28804784
Lancet Oncol. 2020 Sep;21(9):1173-1187
pubmed: 32758455
J Clin Oncol. 2020 Oct 20;38(30):3528-3537
pubmed: 32749942
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
N Engl J Med. 2011 Dec 29;365(26):2473-83
pubmed: 22204724
Lancet Oncol. 2020 May;21(5):699-709
pubmed: 32305099
J Exp Clin Cancer Res. 2017 Jan 17;36(1):14
pubmed: 28095907
Cell Biochem Biophys. 2015 May;72(1):203-13
pubmed: 25510462
J Med Chem. 2013 Sep 26;56(18):7137-60
pubmed: 23734634
Int J Gynecol Cancer. 2017 Jan;27(1):28-36
pubmed: 27870700
Cancer Res. 2000 Oct 15;60(20):5659-66
pubmed: 11059757
Biomark Cancer. 2019 Jul 05;11:1179299X19860815
pubmed: 31308780
Cancers (Basel). 2019 Nov 13;11(11):
pubmed: 31766284
Mol Cancer Ther. 2019 Feb;18(2):364-375
pubmed: 30530769
J Cell Biochem. 2018 Jul;119(7):6162-6172
pubmed: 29663499
J Proteome Res. 2019 Apr 5;18(4):1691-1702
pubmed: 30706710
Gynecol Oncol. 2005 May;97(2):413-21
pubmed: 15863139
N Engl J Med. 2006 Jan 5;354(1):34-43
pubmed: 16394300
Sci Rep. 2018 Dec 14;8(1):17862
pubmed: 30552344
Gynecol Oncol. 2016 Mar;140(3):537-44
pubmed: 26704638